(Q39149201)

9 September 2017

title

Liquid biopsies come of age: towards implementation of circulating tumour DNA. (English)

1 reference

9 September 2017

0 references

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28233803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Florent Mouliere

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28233803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Richard Baird

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28233803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

5

James D Brenton

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28233803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

Charles Massie

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28233803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Javier Garcia-Corbacho

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28233803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Simon Pacey

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28233803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Nitzan Rosenfeld

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28233803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Carlos Caldas

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28233803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

language of work or name

English

0 references

publication date

24 February 2017

1 reference

9 September 2017

published in

Nature Reviews Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28233803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28233803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28233803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

page(s)

223-238

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28233803%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrc.2017.7

13 June 2020

exact match

0 references

cites work

Origins, structures, and functions of circulating DNA in oncology

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

High fragmentation characterizes tumour-derived circulating DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Elevated cell-free plasma DNA level as an independent predictor of mortality in patients with severe traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Noninvasive monitoring of infection and rejection after lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Presence of fetal DNA in maternal plasma and serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Reduction in diagnostic and therapeutic interventions by non-invasive determination of fetal sex in early pregnancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Digital PCR for the molecular detection of fetal chromosomal aneuploidy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Non-invasive prenatal testing: a review of international implementation and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Evaluation of non-invasive prenatal testing (NIPT) for aneuploidy in an NHS setting: a reliable accurate prenatal non-invasive diagnosis (RAPID) protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Neoplastic characteristics of the DNA found in the plasma of cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Identification of p53 gene mutations in bladder cancers and urine samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Detection and quantification of mutations in the plasma of patients with colorectal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Circulating mutant DNA to assess tumor dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Analysis of circulating tumor DNA to monitor metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Use of research biopsies in clinical trials: are risks and benefits adequately discussed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Commentary on tumor heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Serum tumor markers in breast cancer: are they of clinical value?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Exposure to low-dose ionizing radiation from medical imaging procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Double-stranded DNA in exosomes: a novel biomarker in cancer detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

About the possible origin and mechanism of circulating DNA apoptosis and active DNA release

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Quantitative analysis of the transrenal excretion of circulating EBV DNA in nasopharyngeal carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Brain tumor mutations detected in cerebral spinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Mitochondrial resequencing arrays detect tumor-specific mutations in salivary rinses of patients with head and neck cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Identification of tissue-specific cell death using methylation patterns of circulating DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Rapid clearance of fetal DNA from maternal plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva: A qualitative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Circulating DNA and DNase activity in human blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

High resolution size analysis of fetal DNA in the urine of pregnant women by paired-end massively parallel sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Maternal Plasma DNA Sequencing Reveals the Genome-Wide Genetic and Mutational Profile of the Fetus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Fragment Length of Circulating Tumor DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Cancer therapy monitoring in xenografts by quantitative analysis of circulating tumor DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Nonhematopoietically derived DNA is shorter than hematopoietically derived DNA in plasma: a transplantation model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

The Long and Short of Circulating Cell-Free DNA and the Ins and Outs of Molecular Diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Noninvasive prenatal testing by nanopore sequencing of maternal plasma DNA: feasibility assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Direct quantification of cell-free, circulating DNA from unpurified plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Carrier molecules and extraction of circulating tumor DNA for next generation sequencing in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Single-stranded DNA library preparation for the sequencing of ancient or damaged DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Single-stranded DNA library preparation uncovers the origin and diversity of ultrashort cell-free DNA in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Obesity-induced DNA released from adipocytes stimulates chronic adipose tissue inflammation and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

DNA released by leukemic cells contributes to the disruption of the bone marrow microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Cell-free nucleic acids circulating in the plasma of colorectal cancer patients induce the oncogenic transformation of susceptible cultured cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Allele-specific enzymatic amplification of beta-globin genomic DNA for diagnosis of sickle cell anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Ultrasensitive Detection of Multiplexed Somatic Mutations Using MALDI-TOF Mass Spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Novel electrophoresis mechanism based on synchronous alternating drag perturbation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Winnowing DNA for rare sequences: highly specific sequence and methylation based enrichment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Long-term dual-color tracking of genomic loci by modified sgRNAs of the CRISPR/Cas9 system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Differential strand separation at critical temperature: a minimally disruptive enrichment method for low-abundance unknown DNA mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Integrated digital error suppression for improved detection of circulating tumor DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Detection and quantification of rare mutations with massively parallel sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Rapid Identification of Plasma DNA Samples with Increased ctDNA Levels by a Modified FAST-SeqS Approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Detection of Clonal and Subclonal Copy-Number Variants in Cell-Free DNA from Patients with Breast Cancer Using a Massively Multiplexed PCR Methodology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Detection of circulating tumor DNA in early- and late-stage human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Origin and prognostic value of circulating KRAS mutations in lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

TP53andKRAS2Mutations in Plasma DNA of Healthy Subjects and Subsequent Cancer Occurrence: A Prospective Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Noninvasive Prenatal Testing and Incidental Detection of Occult Maternal Malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Detection of cancer DNA in plasma of patients with early-stage breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: implications for cancer screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel In Vivo Device for Capturing Circulating Tumor Cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Genomic Analysis of Uterine Lavage Fluid Detects Early Endometrial Cancers and Reveals a Prevalent Landscape of Driver Mutations in Women without Histopathologic Evidence of Cancer: A Prospective Cross-Sectional Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Molecular Triage of Premalignant Lesions in Liquid-Based Cervical Cytology and Circulating Cell-Free DNA from Urine, Using a Panel of Methylated Human Papilloma Virus and Host Genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

MicroRNAs accurately identify cancer tissue origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

A Minimally-invasive Blood-derived Biomarker of Oligodendrocyte Cell-loss in Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Subclonal diversification of primary breast cancer revealed by multiregion sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Metastasis as an evolutionary process

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Spatial and temporal diversity in genomic instability processes defines lung cancer evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

FAST-SeqS: a simple and efficient method for the detection of aneuploidy by massively parallel sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Plasma AR and abiraterone-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Development of personalized tumor biomarkers using massively parallel sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Pros: Can tissue biopsy be replaced by liquid biopsy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Cellular barcoding: a technical appraisal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Cell-free nucleic acids as biomarkers in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Co-occurrence of MYC amplification and TP53 mutations in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

21 January 2018

The cancer bloodhounds.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Sense and nonsense in the process of accreditation of a pathology laboratory

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Multi-center evaluation of the novel fully-automated PCR-based Idylla™ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Nanopore sequencing detects structural variants in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Real-time, portable genome sequencing for Ebola surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Rapid Short-Read Sequencing and Aneuploidy Detection Using MinION Nanopore Technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Real-time selective sequencing using nanopore technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Circulating cell free DNA: Preanalytical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Low Input Whole-Exome Sequencing to Determine the Representation of the Tumor Exome in Circulating DNA of Non-Small Cell Lung Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Detection of ultra-rare mutations by next-generation sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity Considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Cellular Uptake of Deoxyribonucleic Acid by Human Tissue Culture Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

The value of serial plasma nuclear and mitochondrial DNA levels in patients with acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Direct measurement of cell-free DNA from serially collected capillary plasma during incremental exercise

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Prenatal DNA diagnosis of a single-gene disorder from maternal plasma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Detection of K-ras mutation in sputum by mutant-allele-specific amplification (MASA)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

PCR-detection of tumor-derived p53 DNA in cerebrospinal fluid.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Reversible acetylation on Lys501 regulates the activity of RNase II

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Presymptomatic Identification of Cancers in Pregnant Women During Noninvasive Prenatal Testing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Inferring expressed genes by whole-genome sequencing of plasma DNA.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

MinION Analysis and Reference Consortium: Phase 1 data release and analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Higher amount of free circulating DNA in serum than in plasma is not mainly caused by contaminated extraneous DNA during separation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Plasma collected from heparinized blood is not suitable for HCV-RNA detection by conventional RT-PCR assay

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Changes in Concentration of DNA in Serum and Plasma during Storage of Blood Samples

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.7

Exercise-induced increases in cell free DNA in human plasma originate predominantly from cells of the haematopoietic lineage.

31 March 2020

1 reference

12 December 2020

Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation

1 reference

12 December 2020

Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer

1 reference

12 December 2020

The clearance and localization of nucleic acids by New Zealand and normal mice

1 reference

12 December 2020

Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis

1 reference

12 December 2020

Free DNA in the serum of cancer patients and the effect of therapy.

1 reference

12 December 2020

Measurement of deoxyribonuclease I activity in human tissues and body fluids by a single radial enzyme-diffusion method

1 reference

12 December 2020

Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay

1 reference

12 December 2020

Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia

1 reference

12 December 2020

DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells.

1 reference

12 December 2020

Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism.

1 reference

12 December 2020

Soluble normal and mutated DNA sequences from single-copy genes in human blood

1 reference

12 December 2020

Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma

1 reference

12 December 2020

1 reference

12 December 2020

Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls

1 reference

12 December 2020

Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC)

1 reference

12 December 2020

Elimination of unaltered DNA in mixed clinical samples via nuclease-assisted minor-allele enrichment

1 reference

12 December 2020

Detection of oncogene mutations in sputum precedes diagnosis of lung cancer.

1 reference

12 December 2020

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC.2017.7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28233803%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

1 reference